Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=53

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03914326-500caf2e",
        "title": "Oral Semaglutide vs Placebo: Number of Participants From Randomization to First Occurrence of CKD Endpoint:Renal Death;Onset of Persistent≥50% Reduction in eGFR (CKD-EPI);Onset of Persistent eGFR(CKD-EPI)<15 mL/Min/1.73 m^2;Initiation of Chronic Renal Replacement Therapy",
        "summary": "112 of 4825 against 129 of 4825; risk difference -0.4 points, 95% interval -1.0 to 0.3; NCT03914326, A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes",
        "record": "/library/comparisons/NCT03914326-500caf2e",
        "nct_id": "NCT03914326",
        "kind": "outcome",
        "participants": 9650,
        "risk_difference": {
          "value": -0.0035233160621761656,
          "lower": -0.0098091679491932,
          "upper": 0.0027301552181075474
        },
        "group_1": "112 of 4,825",
        "group_2": "129 of 4,825",
        "difference": "-0.4 points",
        "interval": "-1.0 to 0.3",
        "trial_title": "A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes"
      },
      {
        "id": "NCT03914326-550f751d",
        "title": "Oral Semaglutide vs Placebo: Number of Participants From Randomisation to First Occurrence of Heart Failure Requiring Hospitalisation or Urgent Heart Failure Visit",
        "summary": "146 of 4825 against 167 of 4825; risk difference -0.4 points, 95% interval -1.1 to 0.3; NCT03914326, A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes",
        "record": "/library/comparisons/NCT03914326-550f751d",
        "nct_id": "NCT03914326",
        "kind": "outcome",
        "participants": 9650,
        "risk_difference": {
          "value": -0.004352331606217615,
          "lower": -0.011471579027712168,
          "upper": 0.0027379720684214803
        },
        "group_1": "146 of 4,825",
        "group_2": "167 of 4,825",
        "difference": "-0.4 points",
        "interval": "-1.1 to 0.3",
        "trial_title": "A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=54",
  "request_id": "sp29Y8ikGTb0y0OJ"
}